Neurotrophic Keratitis Market 2019-2027 | Size, Share, Opportunities and Forecast | Credence Research

The neurotrophic keratitis market is set to highlight rapid growth at a compounded annual growth rate (CAGR) of 5.2% during the forecast period from 2019 to 2027

The latest market report published by Credence Research, Inc. “Global Neurotrophic Keratitis Market–Growth, Future Prospects, Competitive Analysis, 2019-2027,” the global market for neurotrophic keratitis is expected to expand at a CAGR of 5.2 per cent from 2019 to 2027.

Ophthalmologists are currently employing the nerve growth factor (NGF) healing pathway, a neurotrophin that initiates neuronal sprouting through injured and intact neurons, a landmark finding made by RA Nobel laureate, Levi Montalcini. Human cornea produces high affinity NGF receptors that play a major role in stimulating both epithelial and nerve fiber survival and proliferation. Oxervate follows this pathway through all age groups to treat neurotrophic keratitis.

Browse the full report Neurotrophic Keratitis Market – Growth, Future Prospects, Competitive Analysis, 2019 – 2027 report at https://www.credenceresearch.com/report/neurotrophic-keratitis-market

Neurotrophic keratitis is an orphan disease with a rate of 5 per 10,000 people in global prevalence. It is manifested by the damage of the trigeminal nucleus nerve innervations present in the corneal region of the eye, which dampens the healing process of corneal injuries. The treatment approach is adopted according to the different stages of the disease. For the wetness, cleanliness and lubrication of the corneal surface, artificial tears are recommended in all phases. Topical antibiotics are prescribed as a preventive measure against bacterial infection in stage 2 of the disease. The treatment of corneal ulcers is preferred in stage 3 surgical procedures such as Tarsorraphy and amniotic membrane transplantation. Oxervate’s recent approval of a recombinant human nerve growth factor by EMA and USFDA will foster neurotrophic market growth during the forecast period.

North America has a market share of 33% and is currently the largest regional segment on the market for neurotrophic keratitis. According to research findings from the American Academy of Ophthalmology (AAO), approximately 65,000 U.S. citizens are reported to suffer from neurotrophic keratitis. The affordable reimbursement scenario encourages growth in the North American region’s market for neurotrophic keratitis. Europe trails North America and accounts for 28.5 percent market growth mainly due to strategic collaboration between academic research institute and pharmaceutical giants to develop new drugs for neurotrophic keratitis treatment. The European Medical Agency (EMA) has awarded neurotrophic keratitis to orphan disease status and has accelerated its drug development and propaganda for sale on the EU market. Asia Pacific holds a 16 percent market share due to the region’s rising prevalence of neurotrophic keratitis in the geriatric population and rampant growth in ophthalmology over the past decade.

Pharmaceutical companies specializing in providing medication for the treatment of neurotrophic keratitis are Allergan, Plc., Abbott Laboratories, Inc., Bausch & Lomb Incorporated, Bayer AG, CooperVision, Dompe farmaceutici S.p.A., Johnson & Johnson, Novartis AG, ReGenTree, LLC., and Walgreens.

Key Market Movements:

Rising prevalence of neurotrophic keratitis worldwide
The supportive regulatory scenario provided for the growth of neurotrophic keratitis market by the healthcare agencies throughout the globe
The recent approval by EMA and priority review designation awarded by the USFDA will help to flourish the Oxervate market for the treatment of neurotrophic keratitis in North America and Europe

Request For Sample: https://www.credenceresearch.com/sample-request/59723

ToC:
Chapter 1. Preface
………….
Chapter 2. Executive Summary
………….

Chapter 3. Neurotrophic Keratitis Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2018
3.6. Competitive Analysis: Global Neurotrophic Keratitis Market, by Key Players, 2018

Chapter 4. Global Neurotrophic Keratitis Market, by Treatment
4.1. Overview
4.2. Preservative Free Artificial Tears
4.3. Topical Antibiotics
4.4. Tarsorraphy
4.5. Amniotic Membrane Transplantation
4.6. Bandage Contact Lenses
4.7. Recombinant Human Nerve Growth Factor (Oxervate)
4.8. Pipeline Analysis
4.8.1. Phase III Drug
4.8.1.1. RGN-259

Chapter 5. Global Neurotrophic Keratitis Market, by Geography
…………..

Chapter 6. Company Profiles
6.1. Allergan, Plc.
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Abbott Laboratories, Inc.
6.3. Bausch & Lomb Incorporated
6.4. Bayer AG
6.5. CooperVision
6.6. Dompe farmaceutici S.p.A.
6.7. Johnson & Johnson
6.8. Novartis AG
6.9. ReGenTree, LLC.
6.10. Walgreens
……………..toc continued

Browse the full report Neurotrophic Keratitis Market – Growth, Future Prospects, Competitive Analysis, 2019 – 2027 report at https://www.credenceresearch.com/report/neurotrophic-keratitis-market

About Us
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.

Medium: Neurotrophic Keratitis Market: North America is responsible for 33% market share

Contact Info:
Name: Chris Smith
Email: Send Email
Organization: Credence Research
Address: 105 N 1st ST #429, SAN JOSE,, CA 95103, United States
Phone: 18003618290
Website: https://www.credenceresearch.com

Source URL: https://marketersmedia.com/neurotrophic-keratitis-market-2019-2027-size-share-opportunities-and-forecast-credence-research/526774

Source: MarketersMedia

Release ID: 526774